|Trade names||Eurespal, Pneumorel|
|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||14–16 hours|
|Excretion||Urine (90%), feces (~10%)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||260.331 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. The pharmacotherapeutic classification is antitussives. In Russia it was approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.. Russia, Romania, France and other European countries withdrew fenspiride-based drugs from the market due to the risk of QT prolongation and torsades de pointes.
- Montes, B; Catalan, M; Roces, A; Jeanniot, JP; Honorato, JM (1993). "Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial". European Journal of Clinical Pharmacology. 45 (2): 169–72. doi:10.1007/bf00315501. PMID 7901024.
- Płusa T, Nawacka D (Dec 1998). "Efficacy and tolerance of fenspiride in adult patients with acute respiratory tract infections". Pol Merkur Lekarski. 5 (30): 368–71. PMID 10101527.
- "Эреспал® (Eurespal®) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 6 February 2014.
- "Fenspiride containing medicinal products". European Medicines Agency. 2019-02-15. Retrieved 2019-06-12.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|